New data support the potential use of Ofev in children with ILD

Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of Ofev (nintedanib) in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD), German family-owned pharma major Boehringer Ingelheim announced today.

The trial showed encouraging data for both primary endpoints and results were published in the European Respiratory Journal (ERJ) and presented at the European Respiratory Society (ERS) International Congress in Barcelona, Spain.

“Based on the nintedanib mode of action, pre-clinical evidence and the clinical benefit in adults, there was a compelling rationale for examining its effect in children living with interstitial lung disease,” said the coordinating investigator, Prof Robin Deterding, director of the Breathing Institute, Children’s Hospital Colorado. “This trial supports its potential use as a treatment with an acceptable safety profile for children and adolescents, for whom no approved evidence-based therapies exist,” he noted.